Clinical efficacy of <italic style="font-style: italic">Shengxuebao Mixture</italic> in treatment of mice with gastric cancer anemia caused by cyclophosphamide

XU Jing; ZHANG Liming; QI Jiamin; LU Hairui; MI Suicai; HAN Xinpu; CHEN Xinyi; HOU Li

doi:10.16025/j.1674-1307.2026.04.006

您当前的位置：

首页 >

文章列表页 >

Clinical efficacy of Shengxuebao Mixture in treatment of mice with gastric cancer anemia caused by cyclophosphamide

更新时间：2026-06-10

- Clinical efficacy of Shengxuebao Mixture in treatment of mice with gastric cancer anemia caused by cyclophosphamide
- Beijing Journal of Traditional Chinese Medicine Vol. 45, Issue 4, Pages: 461-466(2026)
- 作者机构：
  
  1.北京中医药大学东直门医院血液肿瘤科，北京 100700
  2.宁夏医科大学药学院，宁夏 750004
  3.宁夏回族医药研究所，宁夏 750021
  4.厦门市中医院肿瘤科，厦门 361009
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2026.04.006
  CLC：
- Received：25 March 2025，
  
  Published：25 April 2026
- 稿件说明：
移动端阅览
许晶，张立明，祁加敏，等.生血宝合剂对胃癌小鼠环磷酰胺所致贫血状况改善作用观察［J］.北京中医药，2026，45（4）：461-466.

XU Jing,ZHANG Liming,QI Jiamin,et al.Clinical efficacy of Shengxuebao Mixture in treatment of mice with gastric cancer anemia caused by cyclophosphamide[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(04):461-466.
许晶，张立明，祁加敏，等.生血宝合剂对胃癌小鼠环磷酰胺所致贫血状况改善作用观察［J］.北京中医药，2026，45（4）：461-466. DOI： 10.16025/j.1674-1307.2026.04.006.

XU Jing,ZHANG Liming,QI Jiamin,et al.Clinical efficacy of Shengxuebao Mixture in treatment of mice with gastric cancer anemia caused by cyclophosphamide[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(04):461-466. DOI： 10.16025/j.1674-1307.2026.04.006.

摘要

目的

观察生血宝合剂对胃癌小鼠环磷酰胺所致贫血的改善效果。

方法

将70只雄性BALB/c裸鼠按随机数字表法分为空白对照组、胃癌模型组、胃癌贫血模型组、促红细胞生成素（EPO）组及生血宝低、中、高剂量组，每组10只。除空白对照组外，其他各组均构建胃癌模型；除空白对照组和胃癌模型组外，其他各组经腹腔注射环磷酰胺80 mg/（kg·d），连续4 d，制备胃癌相关性贫血模型。空白对照组、胃癌模型组、胃癌贫血模型组给予0.2 mL/d纯水灌胃，连续14 d；生血宝低、中、高剂量组分别给予生血宝合剂2.92、5.85、11.7 mL/（kg·d）灌胃，连续14 d；EPO组给予0.2 mL/d纯水灌胃，同时腹部皮下注射人重组EPO 150 IU/（kg·d），连续14 d。对比各组小鼠一般状态、体质量、血常规。

结果

胃癌贫血模型组及各给药组外周血血红蛋白（HGB）、红细胞（RBC）、白细胞（WBC）、血小板（PLT）计数均呈先下降后回升趋势。给药第7天，与胃癌贫血模型组比较，胃癌模型组、EPO组HGB水平升高（

0.05）；给药第14天，与胃癌贫血模型组比较，EPO组HGB水平升高（

0.05）。给药第7天，生血宝中剂量组、EPO组HGB水平高于本组给药第0天（

0.05）；给药第14天，各给药组HGB水平升高（

0.05）。给药第7天，各给药组RBC计数与胃癌贫血模型组比较，差异无统计学意义（

0.05）；给药第14天，与胃癌贫血模型组比较，生血宝中、高剂量组RBC计数高（

0.05）。给药第7天，与胃癌贫血模型组比较，生血宝中、高剂量组WBC计数高（

0.05）；给药第14天，与胃癌贫血模型组比较，生血宝低剂量组WBC计数高（

0.05）。给药第7天，与胃癌贫血模型组比较，生血宝低、中剂量组PLT计数高（

0.05）；给药第14天，与胃癌贫血模型组比较，各给药组PLT计数均高（

0.05）。与空白对照组比较，胃癌贫血模型组精神状态较差，活动量明显减少，蜷缩成团，皮色灰暗发紫，体质量不同程度减轻。造模3 d后，小鼠食欲减少，出现个别死亡。与胃癌贫血模型组比较，各给药组一般状况改善。给药第7、14天，各给药组体质量比较，差异无统计学意义（

0.05）。与胃癌贫血模型组比较，生血宝各剂量组肝脏指数、脾脏指数、肾脏指数比较，差异无统计学意义（

05）；与胃癌模型组比较，生血宝中剂量组肾脏指数低（

0.05）。

结论

生血宝合剂可在一定程度上改善胃癌贫血小鼠一般状态，提高小鼠外周血HGB和RBC计数，对WBC和PLT也有一定改善作用。

Abstract

Objective

To investigate the therapeutic effects of

Shengxuebao Mixture

on cyclophosphamide-induced anemia in mice with gastric cancer.

Methods

Seventy male BALB/c nude mice were randomly divided into a blank control group， gastric cancer model group， gastric cancer anemia model group， erythropoietin （EPO） group， and low-， medium-， and high-dose

Shengxuebao Mixture

groups according to a random number table， with 10 mice in each group. Except for the blank control group， the gastric cancer model was established in all groups. Except for the blank control group and gastric cancer model group， mice in the remaining groups received intraperitoneal injections of cyclophosphamide at 80 mg/（kg·d） for 4 consecutive days to establish the gastric cancer-related anemia model. The blank control group， gastric cancer model group， and gastric cancer anemia model group received purified water （0.2 mL/d） by gavage for 14 consecutive days. The low-， medium-， and high-dose

Shengxuebao Mixture

groups received

Shengxuebao Mixture

at doses of 2.92， 5.85， and 11.7 mL/（kg·d）， respectively， by gavage for 14 consecutive days. The EPO group received purified water （0.2 mL/d） by gavage combined with subcutaneous abdominal injection of recombinant human erythropoietin （rhEPO） at 150 IU/（kg·d） for 14 consecutive days. General condition， body weight， and routine blood parameters of the mice were compared among groups.

Results

Peripheral blood hemoglobin （HGB）， red blood cell （RBC）， white blood cell （WBC）， and platelet （PLT） counts in the gastric cancer anemia model group and all treatment groups showed a trend of initial decrease followed by gradual recovery. On treatment

day 7， compared with the gastric cancer anemia model group， HGB levels in the gastric cancer model group and EPO group were significantly increased （

0.05）. On treatment day 14， compared with the gastric cancer anemia model group， HGB levels in the EPO group were significantly increased （

0.05）. On treatment day 7， HGB levels in the medium-dose

Shengxuebao Mixture

group and EPO group were significantly higher than those on treatment day 0 in the same groups （

0.05）. On treatment day 14， HGB levels in all treatment groups were significantly increased （

0.05）. On treatment day 7， compared with the gastric cancer anemia model group， no significant differences in RBC counts were observed among the treatment groups （

0.05）. On treatment day 14， RBC counts in the medium- and high-dose

Shengxuebao Mixture

groups were significantly higher than those in the gastric cancer anemia model group （

0.05）. On treatment day 7， WBC counts in the medium- and high-dose

Shengxuebao Mixture

groups were significantly higher than those in the gastric cancer anemia model group （

0.05）. On treatment day 14， WBC counts in the low-dose

Shengxuebao Mixture

group were significantly higher than those in the gastric cancer anemia model group （

0.05）. On treatment day 7， PLT counts in the low- and medium-dose

Shengxuebao Mixture

groups were significantly higher than those in the gastric cancer anemia model group （

0.05）. On treatment day 14， PLT counts in all treatment groups were significantly higher than those in the gastric cancer anemia model group （

0.05）. Compared with the blank control group， mice in the model groups showed poor mental status， markedly reduced activity， curled posture， grayish-purple skin color， and varying degrees of body weight l

oss. Three days after modeling， reduced appetite and sporadic deaths were observed. Compared with the model groups， the general condition of mice in all treatment groups improved. On treatment days 7 and 14， there were no statistically significant differences in body weight among the treatment groups （

0.05）. Compared with the gastric cancer anemia model group， there were no statistically significant differences in liver， spleen， or kidney indices among the

Shengxuebao Mixture

groups （

0.05）. Compared with the gastric cancer model group， the kidney index in the medium-dose

Shengxuebao Mixture

group was significantly lower （

0.05）.

Conclusion

Shengxuebao Mixture

can improve the general condition of mice with gastric cancer-related anemia to a certain extent， increase peripheral blood HGB levels and RBC counts， and also exert beneficial effects on WBC and PLT counts.

关键词

Keywords

references

DE PUTTER R , GEBOES K , DE MAN M , et al . Treatment of anemia in patients with solid tumors receiving chemotherapy in palliative setting: usual practice versus guidelines [J ] . Acta Clin Belg , 2018 , 73 ( 4 ): 251 - 256 .

侯丽 , 董青 , 田劭丹 , 等 . 肿瘤相关性贫血中医药防治专家共识 [J ] . 北京中医药 , 2021 , 40 ( 1 ): 48 - 52 .

陈小妹 , 刘勇 . 生血宝合剂联合rhu-EPO治疗肿瘤化疗相关性贫血的疗效观察 [J ] . 中国医学创新 , 2019 , 16 ( 30 ): 65 - 69 .

王艳 . 抗肿瘤药物环磷酰胺质量研究 [D ] . 连云港 : 江苏海洋大学 , 2022 .

冯立志 . 健脾补血法对环磷酰胺诱导C57BL/6小鼠骨髓抑制及免疫功能的影响 [D ] . 广州 : 广州中医药大学 , 2016 .

胡梦云 , 付烊 , 莫天栩 , 等 . 茯贞膏对脾肾阳虚型肿瘤相关性贫血大鼠的治疗作用研究 [J ] . 中医临床研究 , 2019 , 11 ( 21 ): 8 - 11 .

刘娟 , 初杰 . 不同提取方法的当归补血汤对化疗贫血模型的药效学研究 [J ] . 辽宁中医药大学学报 , 2011 , 13 ( 8 ): 113 - 115 .

邢秀玲 , 赵海鹰 , 李丽君 , 等 . 党参多糖对环磷酰胺所致小鼠贫血的治疗效果观察 [J ] . 临床误诊误治 , 2022 , 35 ( 1 ): 99 - 102 .

马慧娅 . 戊二醛聚合猪血红蛋白对化疗贫血小鼠治疗作用的初步研究 [D ] . 西安：西北大学 , 2019 .

刘德承 . 抗肿瘤药物致骨髓抑制情况分析 [J ] . 临床合理用药 , 2023 , 16 ( 16 ): 158 - 161 .

胡文香 . 生血宝合剂联合多糖铁复合物治疗妊娠期缺铁性贫血40例效果分析 [J ] . 药品评价 , 2022 , 19 ( 12 ): 724 - 727 .

杨春莲 . 生血宝合剂治疗产后贫血的临床疗效及其安全性 [J ] . 临床合理用药杂志 , 2020 , 13 ( 18 ): 119 - 120 .

王璇 . 生血宝合剂辅助治疗对血液肿瘤患者化疗后毒副反应及免疫功能的影响 [J ] . 新中医 , 2021 , 53 ( 12 ): 136 - 139 .

陈晓峰 , 张一妙 , 朱丽红 . 生血宝合剂的临床应用进展 [J ] . 中成药 , 2024 , 46 ( 5 ): 1589 - 1593 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanisms of Guben Yiliu No. 2 in inhibiting postoperative lung metastasis of triple-negative breast cancer mice via the VEGF/ANG pathway

Efficacy and mechanisms of Buwang Powder in treating Alzheimer's disease

Mechanisms of Liangxue Qushi Zhiyang Formula in treatment of atopic dermatitis in mice based on mitochondrial morphology and fission

Pathogenesis evolution and treatment of gastric cancer with spleen deficiency and toxin accumulation based on the principle of "earth responsible for thorough transformation"

Mechanisms of Yixuesheng Capsules in preventing and treating myelosuppression after chemotherapy

Related Author

ZUO Xi

WANG Xiaomin

NAN Lingshan

YIN Xiaohui

CHEN Dong

ZHANG Ganlin

ZHONG Xinyu

WANG Ning

Related Institution

Department of Oncology， Beijing Hospital of Traditional Chinese Medicine， Capital Medical University

Beijing University of Chinese Medicine

Department of Science and Technology， Beijing University of Chinese Medicine

Key Laboratory of Health Cultivation of the Ministry of Education， Beijing University of Chinese Medicine

First Clinical Medical School， Shaanxi University of Chinese Medicine

⁰

Clinical efficacy of Shengxuebao Mixture in treatment of mice with gastric cancer anemia caused by cyclophosphamide

DOI：10.16025/j.1674-1307.2026.04.006

摘要

Abstract

关键词

Keywords

references